An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
- Conditions
- OnychomycosisTinea Unguium
- Interventions
- Registration Number
- NCT03405818
- Lead Sponsor
- Pfizer
- Brief Summary
This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (a fungal infection) of the toenail in children and adolescents (ages 6 to 16 years).
Following confirmation of eligibility, including laboratory evidence of a fungal organism in the toenail, tavaborole topical solution was applied once daily to all affected toenails for a 48-week treatment period.
Clinical assessment of the extent of infection and safety assessments were performed periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after stopping the treatment).
A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small area of surrounding skin during the first 28 days. These subjects had blood samples analyzed to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical solution in children and adolescents.
- Detailed Description
This was an open-label study to evaluate the safety, tolerability, and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (DSO) of the toenail in pediatric subjects aged 6 to 16 years and 11 months. An eligible subject had a target great toenail (TGT) with at least 20% involvement, with a positive potassium hydroxide (KOH) wet mount and positive fungal culture for T. rubrum or T. mentagrophytes.
Eligible subjects applied tavaborole 5% topical solution, once daily to all affected toenails (the TGT as well as all other toenails having the clinical characteristics of onychomycosis) throughout the 48 week treatment period.
Subjects were evaluated at Screening, Baseline (Day 1), and at Weeks 2, 4, 8, 16, 24, 32, 40, 48, and 52. Each evaluation included a clinical assessment of the AEs and local tolerability evaluation.
Additional procedures were performed as follows:
* Mycology sampling at Screening, Week 24, and Week 52/early termination (ET);
* Clinical disease severity of the TGT at Screening, Week 24, and Week 52/ET;
* Safety laboratory testing at Baseline, Week 24, and Week 52/ET;
In this study, there was a PK subgroup of evaluable subjects aged 12 to 16 years and 11 months studied under maximal use conditions. Subjects in this maximal use subgroup applied the study drug on all 10 toenails, including up to 2 mm of the surrounding skin, for 28 days. On Day 15, a predose PK sample was collected to assess steady state trough level. On Day 29, the study drug application was done at the study site, and PK samples were collected prior to dosing, as well as 4, 6, 8, and 24 hours postdose on Days 29 to 30.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
- males or females, ages >/= 6 years and </= 16 years and 11 months
- clinical diagnosis of distal subungual onychomycosis affecting at least 20% of one of the great toenails (target nail); and with positive KOH and positive culture for T. rubrum or T. mentagrophytes from either great toenail
- the target toenail has proximal subungual onychomycosis, onychomycosis involving the nail lunula, superficial white onychomycosis, dermatophytoma, exclusively lateral disease, or yellow or brown spikes, or has co-infection with certain fungi or molds
- anatomic abnormalities of the toes or toenail
- current or past history of chronic moccasin-type tinea pedis
- current or past history of psoriasis or lichen planus
- history of significant chronic fungal disease (other than onychomycosis)
- diabetes
- immunodeficiency
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Tavaborole 5% Topical Solution Tavaborole 5% Topical Solution All study participants apply study drug
- Primary Outcome Measures
Name Time Method Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Baseline up to 28 days after last dose of study drug (up to Week 52) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious AEs.
Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 24 Baseline, Week 24 Change From Baseline in Hematology Parameter (Hematocrit) at Week 52 Baseline, Week 52 Change From Baseline in Hematology Parameter (Erythrocytes) at Week 24 Baseline, Week 24 Change From Baseline in Hematology Parameter (Hematocrit) at Week 24 Baseline, Week 24 Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 52 Baseline, Week 52 Number of Participants With Local Tolerability Reactions by Severity Baseline up to Week 52 Local tolerability reactions consisted of burning/stinging, induration/edema, oozing and crusting, pruritus, erythema, and scaling. Here 0 indicates None, 1 (Mild), 2 (Moderate) and 3 (severe). Grading details are as follows: Burning/Stinging (0: no stinging/burning, 1: slight warm, 2: definite warm, 3: hot); Induration/Edema (0: no elevation, 1: barely perceptible elevation, 2: clearly perceptible elevation but not extensive, 3: marked and extensive elevation); Oozing and Crusting (0: absent, 1: faint signs of oozing, 2: definite oozing, 3: marked and extensive oozing); Pruritus (0: no pruritus, 1: occasional, slight itching, 2: constant itching which is not disturbing sleep, 3: severe bothersome itching/scratching which is disturbing sleep); Erythema (0: no redness present, 1: faintly detectable erythema; very light pink, 2: dull red, 3: deep/dark red); Scaling (0: no scaling, 1: barely perceptible shedding, 2: obvious but not profuse scaling, 3: heavy scale production).
Number of Participants With Adverse Events (AEs) By Severity Baseline up to 28 days after last dose of study drug (up to Week 52) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment by investigator and defined as: Mild = symptoms barely noticeable to the participant or does not make the participant uncomfortable; moderate = symptoms of a sufficient severity to make the participant uncomfortable; severe = symptoms of a sufficient severity to cause the participant severe discomfort.
Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 52 Baseline, Week 52 Change From Baseline in Hematology Parameter (Erythrocytes) at Week 52 Baseline, Week 52 Change From Baseline in Hematology Parameters (Hemoglobin) at Week 24 Baseline, Week 24 Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 24 Baseline, Week 24 Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 52 Baseline, Week 52 Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 24 Baseline, Week 24 Change From Baseline in Hematology Parameters (Hemoglobin) at Week 52 Baseline, Week 52 Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 24 Baseline, Week 24 Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 24 Baseline, Week 24 Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 52 Baseline, Week 52 Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 52 Baseline, Week 52 Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 24 Baseline, Week 24 Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 52 Baseline, Week 52 Change From Baseline in Vital Sign (Pulse Rate) at Week 24 Baseline, Week 24 Pulse rate was defined as the number of pulsations noted in a peripheral artery per minute after participant rested supine for 5 minutes.
Change From Baseline in Vital Sign (Blood Pressure) at Week 24 Baseline, Week 24 Change From Baseline in Vital Sign (Blood Pressure) at Week 52 Baseline, Week 52 Change From Baseline in Vital Sign (Respiratory Rate) at Week 24 Baseline, Week 24 Respiratory rate was defined as the number of inspirations per minute.
Change From Baseline in Vital Sign (Pulse Rate) at Week 52 Baseline, Week 52 Pulse rate was defined as the number of pulsations noted in a peripheral artery per minute after participant rested supine for 5 minutes.
Change From Baseline in Vital Sign (Respiratory Rate) at Week 52 Baseline, Week 52 Respiratory rate was defined as the number of inspirations per minute.
Percentage of Participants With Complete Cure of Target Great Toenail (TGT) at Week 52 Week 52 Complete cure was defined as completely clear nail, negative fungal culture and negative potassium hydroxide (KOH) wet mount.
- Secondary Outcome Measures
Name Time Method Maximum Observed Plasma Concentration (Cmax) of Tavaborole Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29 Area Under the Plasma Concentration-Time Curve From Hour Zero to Hour 24 (AUC24) of Tavaborole Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29 AUC24 was defined as the area under the plasma concentration-time curve from hour 0 to hour 24. AUC24 was calculated using the linear trapezoidal rule.
Percentage of Participants With Negative Fungal Culture of the Target Great Toenail (TGT) at Weeks 24 and 52 Week 24, 52 Percentage of Participants With Mycological Cure of Target Great Toenail (TGT) at Week 24 and 52 Week 24, 52 Mycological cure was defined as negative mycology of the TGT. Negative mycology was defined as negative fungal culture and negative potassium hydroxide (KOH) wet mount. Participants with only one result for either fungal culture or KOH were excluded from this analysis.
Percentage of Participants With Almost Complete Cure of Target Great Toenail (TGT) at Week 24 and 52 Week 24, 52 Almost complete cure was defined as almost clear nail and negative mycology (negative mycology was defined as negative fungal culture and negative KOH wet mount).
Time to Maximum Observed Plasma Concentration (Tmax) of Tavaborole Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29 Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Tavaborole Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29 Elimination Rate Constant of Tavaborole Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29 Elimination rate constant was defined as the rate at which a drug was removed from the body.
Elimination Half-Life of Tavaborole Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29 Elimination half-life (t1/2) was defined as the time required for the body to eliminate half of the drug than its original concentration.
Percentage of Participants With Clinical Efficacy of Target Great Toenail (TGT) at Week 24 and 52 Week 24, 52 Clinical efficacy target great toenail (TGT) was defined as completely clear nail or almost clear nail.
Trial Locations
- Locations (12)
Madera Family Medical Group
🇺🇸Madera, California, United States
MedStar Health Research Institute - MedStar Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
Stanford University School of Medicine
🇺🇸Palo Alto, California, United States
Doctors Research Network
🇺🇸South Miami, Florida, United States
University Hospital, SUNY Downstate Medical Center
🇺🇸Brooklyn, New York, United States
Skin Specialty Dermatology
🇺🇸New York, New York, United States
Oregon Dermatology & Research Center
🇺🇸Portland, Oregon, United States
West Houston Clinical Research Services LLC
🇺🇸Houston, Texas, United States
Texas Dermatology and Laser Specialists
🇺🇸San Antonio, Texas, United States
Jordan Valley Dermatology Center
🇺🇸West Jordan, Utah, United States
PI Coor Clinical Research, LLC
🇺🇸Burke, Virginia, United States
Cyn3rgy Research
🇺🇸Gresham, Oregon, United States